Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial

scientific article published on April 2005

Immunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1001/JAMA.293.14.1751
P698PubMed publication ID15827314
P5875ResearchGate publication ID7910321

P50authorSteven LockhartQ90942112
Jim ButteryQ105095703
Richard MoxonQ24453739
Jodie McVernonQ54345981
Andrew J. PollardQ64861148
P2093author name stringAnthony Harnden
Anna Riddell
Keith Cartwright
Laura Lane
Tracey Chantler
Linda Diggle
Rhonwen Morris
Jane Bowen-Morris
P433issue14
P407language of work or nameEnglishQ1860
P304page(s)1751-1758
P577publication date2005-04-01
P1433published inThe Journal of the American Medical AssociationQ1470970
P1476titleImmunogenicity and safety of a combination pneumococcal-meningococcal vaccine in infants: a randomized controlled trial
P478volume293

Reverse relations

cites work (P2860)
Q37656908A Comparative Phase I Study of Combination, Homologous Subtype-C DNA, MVA, and Env gp140 Protein/Adjuvant HIV Vaccines in Two Immunization Regimes
Q57276295A clinical trial examining the effect of increased total CRM197 carrier protein dose on the antibody response to Haemophilus influenzae type b CRM197 conjugate vaccine
Q39397815A randomized study comparing the safety and immunogenicity of a conjugate vaccine combination containing meningococcal group C and pneumococcal capsular polysaccharide--CRM197 with a meningococcal group C conjugate vaccine in healthy infants: challe
Q60469224A tetravalent meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine is immunogenic and well-tolerated when co-administered with Twinrix® in subjects aged 11–17 years: An open, randomised, controlled trial
Q36732495Active immunization of premature and low birth-weight infants: a review of immunogenicity, efficacy, and tolerability
Q37099250Anti-polyribosylribitol phosphate antibody concentrations and avidities in children since the start of Haemophilus influenzae type b immunization of infants in the United Kingdom
Q36797196Bacterial meningitis: the impact of vaccination
Q38911521Baseline polysaccharide-specific antibodies may not consistently inhibit booster antibody responses in infants to a serogroup C meningococcal protein-polysaccharide conjugate vaccine
Q36446881Combination conjugate vaccines
Q37077660Combination vaccines containing DTPa-Hib: impact of IPV and coadministration of CRM197 conjugates
Q37872958Comparative effects of carrier proteins on vaccine-induced immune response
Q24235722Conjugate vaccines for preventing meningococcal C meningitis and septicaemia
Q24244951Conjugate vaccines for preventing meningococcal C meningitis and septicaemia
Q41812746Effect of increased CRM₁₉₇ carrier protein dose on meningococcal C bactericidal antibody response
Q42248845Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain
Q37951530Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules
Q37769874Glycoconjugate vaccines and immune interference: A review
Q36026108Haemophilus influenzae type b reemergence after combination immunization
Q37163685Immune Responses in U.S. Military Personnel Who Received Meningococcal Conjugate Vaccine (MenACWY) Concomitantly with Other Vaccines Were Higher than in Personnel Who Received MenACWY Alone
Q83374772Immunogenicity and safety of CRM₁₉₇ conjugated 9-valent pneumococcal and meningococcal C combination vaccine in healthy infants
Q79193785Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs
Q39605431Immunogenicity of a heptavalent conjugate pneumococcal vaccine administered concurrently with a combination diphtheria, tetanus, five-component acellular pertussis, inactivated polio, and Haemophilus influenzae type B vaccine and a meningococcal gro
Q51824053Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.
Q38183156Neisseria meningitidis B vaccines: recent advances and possible immunization policies.
Q36153895New combination vaccines still need a boost
Q34114188Overview of the development and current use of CRM(197) conjugate vaccines for pediatric use.
Q36600371Pneumococcal conjugate vaccines: emerging clinical information and its implications
Q85115140Randomised, controlled trial of concomitant pneumococcal and meningococcal conjugate vaccines
Q51963509Safety and immunogenicity of CRM197-conjugated pneumococcal-meningococcal C combination vaccine (9vPnC-MnCC) whether given in two or three primary doses.
Q45393967Safety of the 11-valent pneumococcal vaccine conjugated to non-typeable Haemophilus influenzae-derived protein D in the first 2 years of life and immunogenicity of the co-administered hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B,
Q31158788Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data
Q31049522Sex-dependent immune responses to infant vaccination: an individual participant data meta-analysis of antibody and memory B cells.
Q37613613Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity
Q37621061The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity.
Q38160248The history of pneumococcal conjugate vaccine development: dose selection
Q37376987The influence of carrier protein on the immunogenicity of simultaneously administered conjugate vaccines in infants
Q80754930WHO expert consultation on serotype composition of pneumococcal conjugate vaccines for use in resource-poor developing countries, 26-27 October 2006, Geneva
Q93633809What's new in the other general journals

Search more.